1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited

LALPATHLAB.NS
Dr. Lal PathLabs LimitedIN flagNational Stock Exchange of India
1,582.60
INR
+13.00
- -
264.26BMarket Cap
Dr. Lal PathLabs Limited
LALPATHLAB.NS
(National Stock Exchange of India)

Recent

price

1,582.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.35
20.7
27.33
33.76
61.01
48.16
56.12
64.52
73.09
80.73
95.78
126.22
121.68
133.95
147.74
115.78
Revenue per Share
1.76
2.71
3.34
4.82
8.85
8.05
9.51
10.42
12.1
13.71
17.66
20.85
14.41
21.52
29.24
22.64
Basic EPS, GAAP
1.07
2.84
4.14
3.94
8
6.96
7.36
7.61
10.72
12.4
20.51
-1.78
24.83
28.75
30.92
- -
Free Cash Flow per Basic Share
0.9
0.58
0.91
0.58
0.96
0.95
2.29
1.94
3.35
9.44
6.03
7.06
6.22
12.1
12.44
- -
Dividend per Share
3.13
4.67
7.06
13.47
26.92
23.71
30.27
40.27
48.72
52.95
64.48
78.14
86.52
99.88
116.67
- -
Book Value per Share
3.14
4.46
6.8
10.32
26.26
27.03
33.93
45.41
54.81
56.54
68.52
35.26
47.88
62.14
84.48
- -
Tangible Book Value per Share
165
165
165
165
108
164
163
164
165
165
165
165
166
166
167
167
Basic Weighted Avg Shares
2,373
3,422
4,517
5,579
6,596
7,913
9,124
10,569
12,034
13,304
15,812
20,874
20,166
22,265
24,612
19,320
Sales/Revenue/Turnover
18.64
19.85
17.37
20.39
19.4
23.04
34.57
34.31
34.28
20.45
23.05
35.31
17.43
20.97
22.77
22.48
Operating Margin (%)
136
198
204
272
282
283
275
331
382
728
772
1,081
1,502
1,436
1,419
1,131
Depreciation Expense
291
447
551
796
957
1,322
1,546
1,707
1,992
2,259
2,916
3,448
2,388
3,577
4,871
3,777
Net Income, GAAP
33.95
32
30.62
32.67
30.98
33.62
34.3
34.26
33.3
26.7
24.83
26.24
29.88
28.32
21.21
16.99
Effective Tax Rate (%)
12.27
13.07
12.21
14.26
14.51
16.71
16.94
16.15
16.55
16.98
18.44
16.52
11.84
16.07
19.79
19.55
Profit Margin (%)
-199
-67
277
730
1,699
2,888
3,817
5,071
6,753
6,653
8,709
3,752
5,033
6,631
9,612
- -
Working Capital
41
- -
- -
- -
- -
- -
- -
- -
- -
930
1,102
3,055
2,133
1,030
1,026
- -
LT Debt
935
1,171
1,637
2,333
3,434
4,695
5,980
7,916
9,510
10,540
12,760
15,435
16,995
18,854
22,065
- -
Total Equity
- -
40.09
38.48
38.35
30.57
29.87
39.16
34.66
31.88
18.91
21.26
31.42
11.92
15.94
19.79
- -
Return on Invested Capital (%)
- -
61.16
55.73
45.94
36.71
38.34
34.73
29.41
26.98
25.73
26.34
23.28
14.03
19.54
24.5
- -
Return on Capital (%)
- -
69.35
56.84
46.9
37.25
38.85
35.07
29.65
27.25
26.98
30.11
29.26
17.52
23.12
27.04
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
167
- -
Market Capitalization
466,022
520,041
247,394

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.75%
16.02%
17.03%
Free Cash Flow
-142.01%
-303.71%
7.77%
Net Income, GAAP
19.82%
20.51%
36.17%
Sales/Revenue/Turnover
14.4%
13.69%
10.54%
Total Cash Common Dividend
49.68%
13.58%
3.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,410
6,013
5,389
5,453
22,265
2025
6,019
6,602
5,967
6,024
24,612
2026
6,698
- -
6,598
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.97
6.58
4.89
- -
21.52
2025
6.4
7.76
5.8
- -
29.24
2026
7.94
- -
5.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
12.1
2025
- -
- -
- -
- -
12.44
2026
- -
- -
- -
- -
- -
Similar Companies
Quest Diagnostics Incorporated (DGX)
PharmChem, Inc. (PCHM)
Integrative Health Technologies, Inc. (IHTI)
Cordlife Group Limited (P8A.SI)
iMD Companies, Inc. (ICBU)
Guardant Health, Inc. (GH)
Business
Dr. Lal PathLabs Limited is a leading Indian provider of diagnostic and healthcare testing services. The company operates an extensive network of over 200 laboratories and more than 5,000 specimen collection centers across India, servicing a broad spectrum of pathology, radiology, cardiology, and molecular diagnostics tests. Its core product offerings include blood and urine tests, genomic profiling, myeloid testing for hematological malignancies, autoimmune disorder diagnostics, amyloid typing solutions, comprehensive health screening packages such as SwasthFit, and advanced diagnostics powered by technologies like next-generation sequencing and artificial intelligence. Founded in 1949 and headquartered in Gurugram, India, Dr. Lal PathLabs serves patients and healthcare providers both domestically and internationally. The company focuses on delivering high-quality, accessible diagnostic services across metropolitan, tier 1, and expanding tier 3 and tier 4 cities. It operates specialized divisions like Genevolve for genomics. It has partnerships with prominent technology firms such as Illumina to enhance its genomic testing capabilities, exemplified by the recent integration of Illumina’s NovaSeq X Series, advancing its precision and research offerings. In recent developments, Dr. Lal PathLabs launched India's first dedicated Complement Testing Lab in November 2025 to support autoimmune and kidney disease diagnostics. It has also entered a strategic partnership with SAMRIDH Impact Solutions to bolster healthcare innovation and support early-stage diagnostic startups. The company is actively pursuing growth through geographic expansion, particularly targeting acquisitions to strengthen its presence in South India, a region historically underpenetrated by its services. It is considering acquisitions in the INR 3,000-4,000 crore range to consolidate its market leadership. Alongside expansion, it continues to invest in digital technologies, artificial intelligence, and laboratory information systems to improve operational efficiency and patient experience. Dr. Lal PathLabs holds key industry accreditations including ISO 9001 and NABL certification. It operates in the diagnostic and healthcare sectors with a focus on clinical laboratories, pathology, radiology, cardiology, and molecular diagnostics markets. The company has strengthened its product and service portfolio with advanced test launches, including specialized amyloid typing under expert international guidance and ongoing development of bundled health packages for underserved markets. Overall, Dr. Lal PathLabs Limited is a dominant diagnostics chain in India with substantial investments in technological advancement, strategic partnerships, and market expansion initiatives, underscoring its commitment to accessible and cutting-edge diagnostic healthcare solutions.